Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 198 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Loss Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational Results available

I-Tracking Neurodegeneration in Early Wolfram Syndrome

NCT03951298
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational

Study of Usher Syndromes, Type 1 and Type 2

NCT00001347
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 10:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Advanced Spatiomotor Rehabilitation for Navigation in Blindness & Visual Impairment

NCT05377853
View directory record Official record
Conditions
Blindness, Blindness, Acquired, Low Vision, Blindness, Complete
Interventions
Cognitive-Kinesthetic Navigational Training
Behavioral
Lead sponsor
Smith-Kettlewell Eye Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment

NCT06067607
View directory record Official record
Conditions
Cortical/Cerebral Visual Impairment, Cerebral Palsy
Interventions
eye gaze technology
Other
Lead sponsor
Rockhurst University
Other
Eligibility
2 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

NCT07184086
View directory record Official record
Conditions
Obesity
Interventions
CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional

Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment

NCT07149259
View directory record Official record
Conditions
Low Vision Aids
Interventions
At Home Use
Device
Lead sponsor
Brooks Rehabilitation
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults

NCT04820218
View directory record Official record
Conditions
Visual Impairment, Myopia, Hyperopia, Astigmatism
Interventions
With Try-on glasses
Device
Lead sponsor
EyeQue Corp.
Industry
Eligibility
30 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newark, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Providing Access to the Visual Environment

NCT00341744
View directory record Official record
Conditions
Vision Impairment
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 21 Years
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Wayfinding Information Access System for People With Vision Loss

NCT00829036
View directory record Official record
Conditions
Blindness
Interventions
Wayfinding Prototype
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Visual Retraining After Stroke

NCT06121219
View directory record Official record
Conditions
Vision Loss Partial, Vision; Loss, Both Eyes, Hemianopia Homonymous, Hemianopia, Quadrantanopia, Stroke, Ischemic, Stroke - Occipital Infarction, Cortical Blindness
Interventions
Training in the Blind Field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional

PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery

NCT07185971
View directory record Official record
Conditions
Homonymous Hemianopsia, Homonymous Quadrantanopia
Interventions
PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
Device
Lead sponsor
NeuroAEye LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Cedar Rapids, Iowa • Prospect, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Factors in Learning And Plasticity: Healthy Vision

NCT05439759
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

NCT05135195
View directory record Official record
Conditions
Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Environmental Localization Mapping and Guidance for Visual Prosthesis Users

NCT04359108
View directory record Official record
Conditions
Retinitis Pigmentosa, Visual Impairment, Visual Prosthesis
Interventions
Navigation system mode: Argus Vision, Navigation system mode: Depth Vision, Navigation system mode: Depth Vision with Haptic / Audio, Navigation system mode: Haptic / Audio, Navigation system mode: High Field-of-View Depth Vision, Distance test vision mode: Low Resolution / Low Field-of-View, Distance test vision mode: Low Resolution / High Field-of-View, Distance test vision mode: High Resolution / Low Field-of-View, Distance test vision mode: High Resolution / High Field-of-View
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 10:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational Results available

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

NCT03889444
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

NCT04925687
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Intravitreal autologous CD34+ cells
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 21, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Fluoxetine for Visual Recovery After Ischemic Stroke

NCT02737930
View directory record Official record
Conditions
Acute Stroke, Visual Field Loss
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Bogachan Sahin
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 21, 2026, 10:23 PM EDT
Active, not recruiting Phase 3 Interventional

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NCT05112861
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 10:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sight and Hearing Investigation Into Effects on Delirium

NCT06176625
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
Interventions
Communication Signage, Amplifier Use
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
1,543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 10:23 PM EDT